Gsk Share Discussion Threads

[abdullla] 24/1/2024 14:48

Left hand wants to know what the right hand is doing.

[alibizzle] 24/1/2024 13:46

Am I right in saying that the Delaware zantac ruling is going to take 6 months as stated in The Times , so nothing decided this week ?

[disc0dave46] 22/1/2024 18:29

Good luck. Prefer to see how this week pans out.

[tuftymatt] 22/1/2024 10:00

Agree and I made a small top up.

Risky I know but I hold at a good trading average and am confident of a run to 1600.

Good luck all 👍🏻

[disc0dave46] 22/1/2024 09:31

Just folks taking profits after the recent rise. It's only just started and will last 3 days so nothing would have been decided on the morning if the first day.

[abdullla] 22/1/2024 09:13

This share price drop indicates bad news in the court.

[disc0dave46] 21/1/2024 11:17

As mentioned by zho, pre-trial hearings on Zantac claims starts tomorrow which will have a significant bearing on share price action.

[tradermichael] 18/1/2024 15:39

IN @ 1551.01p ..... ;o)

[tradermichael] 18/1/2024 15:21

APH - p/e is worrying ..... ;0)

[abdullla] 18/1/2024 14:55

GSK Abouturn !

[blackhorse23] 18/1/2024 14:49

Money moving to APH , better dividend yield health care company

[rikky72] 18/1/2024 11:28

Your name is apt

[garycook] 18/1/2024 07:52

halfpenny, Shorters have their teeth into PFC. Keep ramping PFC.

[dplewis1] 18/1/2024 07:49

No short interest declared.. your info is false

[halfpenny] 18/1/2024 07:19

Looks like Shorters have their teeth into GSK.

Be Careful at these levels.

[laurence llewelyn binliner] 17/1/2024 19:15

A solid day here in a sea of red in my PF, GSK doing very well, as is HLN since the spin off while they smash their debt down, I continue to hold both..

[tradermichael] 17/1/2024 14:44

GSK raises $1.24 bln from latest Haleon stake sale.

GSK sold around 300 million shares in its spun-off unit at a price of 326 pence per share.

[tuftymatt] 17/1/2024 12:34

Yeah I agree it's holding up really well.

If we get a market rally off this start of the year dip I think 1625 is an easy target.

Good luck all 👍🏻

[rikky72] 17/1/2024 12:28

Resilient today amid a wider sell off; let's see what the yanks give us later

[zho] 16/1/2024 13:58

And some more from Shore's Sean Conroy:

"Pre-trial hearings on the admissibility of expert testimony are scheduled on 22-25 Jan and should serve as an important indicator as to whether GSK is likely to make further settlements in 2024," Conroy said.

However, he added: "As a reminder, the analogous Daubert hearings in the federal-level multi-district litigation ruled in favour of GSK (and other manufacturers) and resulted in the outright, robust dismissal of all MDL cases given the lack of credible scientific evidence."

Conroy said that a worst-case scenario, in which Zantaz litigation costs GSK a total of $30.0bn, is currently being reflected in the share price. "[We] highlight any further clarity could support a material rerating of share; we have updated our sensitivity analysis and believe there remains a compelling risk-reward profile ahead of further updates on Zantac," he said.

The broker has lifted its target price from 1,850.0p to 2,000.0p and kept a 'buy' rating.

[patientcapital] 16/1/2024 12:56

Can't believe UBS didn't already cover GSK. I know Phillips & Drew did.

[dplewis1] 16/1/2024 11:50

GSK - UBS assumes coverage with buy rating and target price of 1860p. Morgan Stanley raises target price to 1730p from 1535p

[geckotheglorious] 16/1/2024 09:42

Shore Capital: GSK discount is ‘unwarranted’
GSK (GSK) continues to trade on an ‘unwarranted’ discount to its peer group as litigation costs ‘disproportionately’ overshadow the pharmaceuticals giant, says Shore Capital.

Analyst Sean Conroy reiterated his ‘buy’ recommendation and increased the ‘fair value’ target price from £18.50 to £20.00 on the Citywire Elite Companies AAA-rated stock, which was trading at £15.79 on Monday.

‘We continue to view the current discount to peers as unwarranted and largely attributable to misguided assumptions on the potential cost of Zantac litigation,’ Conroy said.

‘This has disproportionately overshadowed the improved and increasingly attractive growth story we believe GSK delivered in 2023.’

He noted that respiratory virus vaccine Arexvy ‘smashed expectations in its debut quarter’ and said sustaining this momentum in the drug ‘could provide a key source of upgrades in 2024, albeit further uptake of (shingles medication) Shingrix ex-US will be needed to realise these’.

Conroy added that ‘progress across several areas of the pipeline and additional bolt-on deals can also be expected that could further improve sentiment around long-term growth’.